U.S. markets closed
  • S&P Futures

    3,827.00
    -7.00 (-0.18%)
     
  • Dow Futures

    30,876.00
    -60.00 (-0.19%)
     
  • Nasdaq Futures

    11,794.00
    -14.50 (-0.12%)
     
  • Russell 2000 Futures

    1,736.40
    -5.30 (-0.30%)
     
  • Crude Oil

    100.10
    +0.60 (+0.60%)
     
  • Gold

    1,769.50
    +5.60 (+0.32%)
     
  • Silver

    19.14
    +0.01 (+0.07%)
     
  • EUR/USD

    1.0267
    -0.0003 (-0.03%)
     
  • 10-Yr Bond

    2.8090
    -0.0800 (-2.77%)
     
  • Vix

    27.54
    +0.01 (+0.04%)
     
  • GBP/USD

    1.1970
    +0.0018 (+0.15%)
     
  • USD/JPY

    135.2380
    -0.6040 (-0.44%)
     
  • BTC-USD

    19,898.57
    -282.80 (-1.40%)
     
  • CMC Crypto 200

    430.28
    -9.74 (-2.21%)
     
  • FTSE 100

    7,025.47
    -207.18 (-2.86%)
     
  • Nikkei 225

    26,097.79
    -325.68 (-1.23%)
     

Rockwell Medical, Inc. to Report First Quarter 2022 Financial and Operating Results on May 16, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WIXOM, Mich., May 11, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, May 16 at 4:15 PM ET to discuss its financial results for the three months ended March 31, 2022, and recent operational highlights.

(PRNewsfoto/Rockwell Medical, Inc.)
(PRNewsfoto/Rockwell Medical, Inc.)

To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time and refer to conference ID 2599375. A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

To submit questions in advance, please email your questions to invest@rockwellmed.com.

About Rockwell Medical

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients' lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/rockwell-medical-inc-to-report-first-quarter-2022-financial-and-operating-results-on-may-16-2022-301544919.html

SOURCE Rockwell Medical Technologies, Inc.